Company profile
Pharmaceuticals, innovative medicines · Basel, Switzerland · novartis.com
Novartis is a global innovative medicines company focused on four core therapeutic areas and multiple technology platforms spanning chemistry, biotherapeutics, xRNA, radioligand therapy, gene and cell therapy. Its current direction emphasizes launch execution, pipeline productivity, operational excellence, disciplined capital allocation, while also expanding access and investing in digital and AI enabled capabilities.
The company says it is a pure-play innovative medicines company centered on cardiovascular-renal-metabolic, immunology, neuroscience, oncology.
Management states the four therapeutic areas are the core of the business and that each has significant in-market and pipeline assets.
Novartis is investing in established and emerging platforms to support development and scale.
The company highlights chemistry and biotherapeutics, plus gene and cell therapy, radioligand therapy, xRNA as prioritized platforms.
Public strategy pages frame technology as a means to improve research and broaden patient access.
The strategy page says Novartis uses advanced technological approaches in research and development to ensure and expand access to modern, innovative medicines.
Recent reporting shows continued investment in transformation programs and cyber resilience.
The annual report says Novartis launched the Lean Digital Core program to future-proof processes and technologies, the board reviewed enterprise data governance and cyber security.
Novartis appears to be building a more standardized, data driven, AI enabled enterprise technology stack, with emphasis on digital workflows, analytics platforms, cyber resilience.
Public materials indicate cloud based data and analytics, enterprise workflow modernization, stronger governance around data, AI, security.
This is a neutral public preview. Sign in to generate your own personalized brief, with stakeholder angles, talk tracks and where your solution fits, tailored to how you sell.
Generate a full briefYour first brief is free, no card required.
Evidence confidence 84/100. Generated 2026-07-03 from public sources.